NEW YORK, Oct. 25, 2019 (GLOBE NEWSWIRE) -- IBIO, INC. (NYSE AMERICAN: IBIO)  announced the pricing of an underwritten public offering with expected total gross proceeds of approximately $5,000,000, before deducting underwriting discounts, commissions and other offering expenses payable by the Company.

About iBio, Inc.

iBio is a global leader in plant-based biopharmaceutical contract development and cGMP manufacturing services. Our wholly-owned subsidiary, iBio CDMO LLC, uses the FastPharming™ System – which combines plant protein expression, automated hydroponics, and glycan engineering technologies – to rapidly deliver gram quantities of high-quality biologics for research or further manufacturing uses from its 120,000 square foot facility in Bryan, Texas. In addition to contract manufacturing, iBio also offers process development, bioanalytical, and fill-finish services, along with Factory Solutions for the design and build of facilities for plant-made monoclonal antibodies, vaccines, bioinks and more. iBio also uses its advanced manufacturing capabilities in the development of its own therapeutic pipeline, including its lead asset, IBIO-100 for the treatment of fibrotic diseases. For more information, visit www.ibioinc.com.